ODI fundamentals
ODI PHARMA AB financial statements, including revenue, expenses, and profit
The annual and quarterly earnings report below will help you understand the performance of ODI.
Q4 '19
Q2 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
−5.00 M
0.00
5.00 M
10.00 M
15.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: SEK
Q4 '19
Jun 2019
Q2 '20
Dec 2019
Q1 '21
Sep 2020
Q2 '21
Dec 2020
Q3 '21
Mar 2021
Q4 '21
Jun 2021
Q1 '22
Sep 2021
Q2 '22
Dec 2021
Q3 '22
Mar 2022
Q4 '22
Jun 2022
Q1 '23
Sep 2022
Q2 '23
Dec 2022
Q3 '23
Mar 2023
Q4 '23
Jun 2023
Q1 '24
Sep 2023
Q2 '24
Dec 2023
Q3 '24
Mar 2024
Q4 '24
Jun 2024
Q1 '25
Sep 2024
Q2 '25
Dec 2024
Q3 '25
Mar 2025
TTM
Total revenueYoY growth
27.37 K
+92.33%
528.21 K
+1,786.05%
1.18 K
−98.40%
13.86 M
+128,189.41%
7.54 M
+27,460.17%
143.80 K
−72.78%
0.00
−100.00%
2.93 M
−78.82%
10.62 M
−2.65 M
−1.70 M
−1.85 M
−12.40 M
−8.34 M
−1.58 M
−497.00
−2.85 M
−12.77 M
Gross profitYoY growth
−2.63 M
−9.86%
−1.18 M
+23.67%
−1.85 M
−7.86%
1.45 M
—
−791.68 K
+69.87%
−1.44 M
−22.01%
−497.00
+99.97%
82.02 K
−94.35%
−2.15 M
Operating incomeYoY growth
−2.63 M
−9.86%
−1.18 M
+23.67%
−1.85 M
−7.86%
1.45 M
—
−791.68 K
+69.87%
−1.44 M
−22.01%
−2.31 M
−24.71%
82.02 K
−94.35%
−4.45 M
94.71 K
−266.00 K
2.80 M
−61.91 K
−319.56 K
−32.66 K
−254.12 K
−422.62 K
−1.03 M
Pretax incomeYoY growth
−2.53 M
−6.51%
−1.44 M
+9.74%
946.53 K
—
1.39 M
—
−1.11 M
+56.12%
−1.47 M
−1.78%
−2.56 M
−370.73%
−340.61 K
−124.51%
−5.48 M
−2.53 M
−1.44 M
946.53 K
1.30 M
−1.21 M
−1.47 M
−2.56 M
−340.61 K
−5.58 M
Net incomeYoY growth
−2.53 M
−6.51%
−1.44 M
+9.95%
946.53 K
—
1.30 M
—
−1.21 M
+52.27%
−1.47 M
−1.78%
−2.56 M
−370.73%
−340.61 K
−126.25%
−5.58 M
−2.53 M
−1.44 M
946.53 K
1.30 M
−1.21 M
−1.47 M
−2.56 M
−340.61 K
−5.58 M
Basic earnings per share (Basic EPS)YoY growth
−0.17
−6.47%
−0.09
+9.99%
0.06
—
0.09
—
−0.08
+52.26%
−0.10
−1.80%
−0.16
−365.06%
−0.02
−125.15%
−0.36
Diluted earnings per share (Diluted EPS)YoY growth
−0.17
−6.47%
−0.09
+9.99%
0.06
—
0.09
—
−0.08
+52.26%
−0.10
−1.80%
−0.16
−365.06%
−0.02
−125.15%
−0.36
15.25 M
15.25 M
15.25 M
15.25 M
15.25 M
15.25 M
15.57 M
15.92 M
—
15.25 M
15.25 M
15.25 M
15.25 M
15.25 M
15.25 M
15.57 M
15.92 M
—
EBITDAYoY growth
−2.63 M
−9.89%
−1.18 M
+23.67%
−1.85 M
−7.88%
1.45 M
—
−790.96 K
+69.88%
−1.44 M
−22.05%
−2.31 M
−24.73%
82.48 K
−94.32%
−4.45 M
EBITYoY growth
−2.63 M
−9.86%
−1.18 M
+23.67%
−1.85 M
−7.86%
1.45 M
—
−791.68 K
+69.87%
−1.44 M
−22.01%
−2.31 M
−24.71%
82.02 K
−94.35%
−4.45 M
−2.65 M
−1.70 M
−1.85 M
−12.40 M
−8.34 M
−1.58 M
−2.31 M
−2.85 M
−15.08 M